Abstract: The present invention relates to methods for producing immuno-stimulatory autologous dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer.

Abstract: A real-time automated method to diagnose and/or detect stroke and engage the patient, care-takers, emergency medical system and stroke neurologists in the management of this condition includes the steps of continuously measuring natural limb activity, conveying the measurements to a cloud based real-time data processing system, identifying patient specific alert conditions, and determining solutions for acting upon needs of the patient. The system by which the method is implemented includes at least one body worn sensor continuously measuring natural limb activity and a patient worn data transmission device conveying the measurements to a cloud based real-time data processing system that identities patient specific alert conditions and determines solutions for acting upon needs of the patient.

Abstract: Techniques are described for implementing a class of multimode bosonic codes that protect against errors within an ancilla qubit coupled to a bosonic system, that can be realized experimentally. A logical qubit state is represented by the states of multiple different modes of one or more bosonic systems, which may include multiple modes of a single bosonic system and/or single modes from multiple bosonic systems. Techniques for correcting errors are also described. In particular, a series of operations are described that autonomously detect and correct errors by repeatedly performing a sequence of operations that are each applied to the multiple bosonic modes and/or to the ancilla qubit that is coupled to each of the bosonic modes. The codes allow ancilla errors to propagate to the modes of the bosonic system as correctable errors, where they can be corrected, instead of presenting as logical errors in the ancilla qubit.

Abstract: Techniques are describing for designing and operating a quantum oscillator. In contrast with conventional approaches to operating a quantum oscillator, the present techniques relate to an oscillator design that has less bare nonlinearity than is conventionally thought to be necessary for efficient operation. Moreover, the oscillator may be driven at a frequency that is detuned away from the frequency at which a nonlinear oscillator is typically driven. In particular, the detuned drive frequency may be substantially different from the typical drive frequency, and furthermore may be a frequency that may be expected to produce a low coherence time without also engineering the reduced nonlinearity described above. As a result, the combination of an engineered reduced nonlinearity combined with a detuned drive may result in a well behaved oscillator with a strong effective nonlinearity that exhibits significantly longer coherence times than conventional quantum oscillators.

Abstract: The present invention provides novel compounds that are quinoline foldamers. Such foldamers stabilize and bind to islet amyloid polypeptide (IAPP). In certain embodiments, the quinoline foldamers of the invention are soluble and cross biological membranes without cellular assistance. The present invention further provides novel methods of preventing or treating diabetes in a subject in need thereof by administering to the subject an effective amount of at least one quinoline foldamer of the invention. The present invention further provides novel methods of preventing or treating a neurodegenerative disease caused by a misfolded and/or unstructured protein in a subject in need thereof by administering to the subject an effective amount of at least one quinoline foldamer of the invention.

Abstract: The present disclosure provides antibodies that bind to ALK1 and methods/uses of the disclosed antibodies for treating various conditions (e.g., atherosclerosis). The present disclosure provides anti-ALK1 antibodies, comprising the complementarity determining regions (CDRs) of a heavy chain variable sequence and a light chain variable sequence selected from: the heavy chain variable sequence of SEQ ID NO: 2 and the light chain variable sequence of SEQ ID NO: 3. In some embodiments, the disclosed antibodies bind to human ALK1, murine ALK1, cynomolgus ALK1, or a combination thereof. The present disclosure also provides pharmaceutical compositions comprising an anti-ALK1 antibody accordingly to any one of the foregoing aspects or embodiments and a pharmaceutically acceptable carrier.

Abstract: The present invention includes compositions and methods for identification of membrane targets for enhancement of T cell activity against a disease, disorder or condition, and/or enhancing T cell anti-tumor activity in a subject in need thereof. In some embodiments, the disease is cancer. In further embodiments, the cancer is glioblastoma (GBM) or breast cancer.

Abstract: The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

Abstract: The disclosed technology relates to methods, transcriptomics systems, and non-transitory computer readable media for enabling natural language transcriptomics analysis. In some examples, genomic data including gene expression profiles for cells is transformed into sequences of genes ordered by expression level for each of the cells. The sequences of genes are annotated with metadata in a natural language format. A large language model (LLM) is then fine-tuned using the annotated sequences. The LLM is pretrained for natural language processing (NLP) tasks. The fine-tuned LLM is applied to generate and output a result in response to a received prompt in the natural language format. Thus, the LLMs of this technology advantageously both generate and interpret transcriptomics data and interact in natural language to generate meaningful text from cells and valid genes, among many other types of results.

Abstract: Provided herein are novel antibacterial compounds of Formula I. The compounds can be made through enzymatic oxidative dimerization in the presence of a suitable organism and one or more metal salts. Pathogenic bacteria exposed to the compound of Formula I do not develop resistance to these compounds even after prolonged exposure. Also provided herein are methods of treating bacterial infections, and method of killing or disinfecting bacteria.

Abstract: The invention features methods and compositions for eliciting an anti-tumor response in a subject comprising administering to the subject a pHLIP? construct comprising an antibody recruiting molecule linked to one or more pHLIP? peptides by a non-cleavable linker compound. The construct increases the amount of the antibody recruiting molecule on the surface of a diseased cell.

Abstract: Techniques for performing quantum information processing using an asymmetric error channel are provided. According to some aspects, a quantum information processing includes a data qubit and an ancilla qubit, the ancilla qubit having an asymmetric error channel. The data qubit is coupled to the ancilla qubit. The ancilla qubit may be driven with a stabilizing microwave field to create the asymmetric error channel.

Abstract: In various aspects and embodiments the invention provides a method of treating epilepsy in a subject in need thereof, the method comprising contacting a target cell of the subject with an effective amount of an HCN4 disrupting agent.

Abstract: Provided herein, in some embodiments, are compositions and methods for producing a molecular expression map of a biological sample using Deterministic Barcoding in Tissue for spatial omics sequencing (DBiT-seq).

Abstract: The present invention relates to a system, device, and method for the high throughput multiplexed detection of a wide number of compounds. The invention comprises of a microwell array coupled to a capture agent array to form a plurality of interfaces between a microwell and a set of immobilized capture agents. The set of capture agents comprises a plurality of distinguishable features, with each feature corresponding to the detection of a particular compound of interest. In certain embodiments, each microwell is configured to contain a single cell. The invention is therefore capable of performing a high throughput analysis of single cell profiles, including profiles of secreted compounds.

Abstract: A medication delivery assistance device includes a chamber housing that defines an interior space. A first input port is at a first end of the chamber housing, an output port is at a second end of the chamber housing, and a second input port is in the chamber housing. The first input port is configured to receive a portion of an inhaler that is configured to deliver medication into the interior space. The output port has a user interface that is configured to define a medication flow path from the first input port through the interior space and out the output port. The second input port is configured to receive at least a portion of an external fluid source that is configured to deliver a fluid into the interior space to accelerate movement of the medication along the medication flow path.

Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Abstract: A scattering-type scanning near-field optical microscope at cryogenic temperatures (cryo-SNOM) configured with Akiyama probes for studying low energy excitations in quantum materials present in high magnetic fields. The s-SNOM is provided with atomic force microscopy (AFM) control, which predominantly utilizes a laser-based detection scheme for determining the cantilever tapping motion of metal-coated Akiyama probes, where the cantilever tapping motion is detected through a piezoelectric signal. The Akiyama-based cryo-SNOM attains high spatial resolution, good near-field contrast, and is able to perform imaging with a significantly more compact system capable of handling simultaneous demands of vibration isolation, low base temperature, precise nano-positioning, and optical access. Results establish the potential of s-SNOM based on self-sensing piezo-probes, which can easily accommodate near-IR and far-infrared wavelengths and high magnetic fields.

Abstract: Systems and methods for implementing holographic quantum circuits on compact quantum computing systems are provided. Compact quantum computing systems include systems having fewer physical qubits than the number of quantum modes to be instantiated during execution of the quantum circuit. Techniques described herein may be used to perform boson sampling techniques, including with application to molecular docking simulations.

Abstract: In one aspect, the invention provides a method for detecting a viral-only or a bacterial-associated respiratory infection in a patient, the method comprising analyzing a respiratory sample to determine levels of at least two respiratory virus infection-associated molecules, at least two bacterial respiratory infection-associated molecules, and comparing the levels of the respiratory virus infection-associated molecules and/or the levels of the bacterial respiratory infection-associated molecules with a predetermined reference level.